'''Ipriflavone''' ([[International Nonproprietary Name|INN]]) (brand name '''Yambolap''') is a [[synthetic compound|synthetic]] [[isoflavone]] which may be used to inhibit bone resorption,<ref name="pmid9263610">{{cite journal |doi=10.1007/s002239900378 |title=In Vitro and in Vivo effects of ipriflavone on bone formation and bone biomechanics |year=1997 |last1=Civitelli |first1=R. |journal=Calcified Tissue International |volume=61 |pages=S12–4 |pmid=9263610}}</ref> maintain bone density and to prevent [[osteoporosis]] in postmenopausal women.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA651|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=651–}}</ref> It is not used to treat osteoporosis. It slows down the action of the [[osteoclast]]s (bone-eroding cells), possibly allowing the [[osteoblast]]s (bone-building cells) to build up bone mass.

 
Ipriflavone has been described as a [[phytoestrogen]].<ref name="ArjmandiBirnbaum2000">{{cite journal|last1=Arjmandi|first1=B. H.|last2=Birnbaum|first2=R. S.|last3=Juma|first3=S.|last4=Barengolts|first4=E.|last5=Kukreja|first5=S. C.|title=The Synthetic Phytoestrogen, Ipriflavone, and Estrogen Prevent Bone Loss by Different Mechanisms|journal=Calcified Tissue International|volume=66|issue=1|year=2000|pages=61–65|issn=0171-967X|doi=10.1007/s002230050012}}</ref> However, this is incorrect, as the drug does not bind to or activate the [[estrogen receptor]] and shows no [[estrogen]]ic effects in [[postmenopausal]] women.<ref name="PetilliFiorelli1995">{{cite journal|last1=Petilli|first1=M.|last2=Fiorelli|first2=G.|last3=Benvenuti|first3=S.|last4=Frediani|first4=U.|last5=Gori|first5=F.|last6=Brandi|first6=M. L.|title=Interactions between ipriflavone and the estrogen receptor|journal=Calcified Tissue International|volume=56|issue=2|year=1995|pages=160–165|issn=0171-967X|doi=10.1007/BF00296349}}</ref><ref name="MelisPaoletti2014">{{cite journal|last1=Melis|first1=Gian Benedetto|last2=Paoletti|first2=A. M.|last3=Cagnacci|first3=A.|last4=Bufalino|first4=L.|last5=Spinetti|first5=A.|last6=Gambacciani|first6=M.|last7=Fioretti|first7=P.|title=Lack of any estrogenic effect of ipriflavone in postmenopausal women|journal=Journal of Endocrinological Investigation|volume=15|issue=10|year=2014|pages=755–761|issn=0391-4097|doi=10.1007/BF03347647}}</ref> The drug prevents [[osteoporosis|bone loss]] via mechanisms that are distinct from those of [[estrogen]]s.<ref name="ArjmandiBirnbaum2000" />
